Soleno Therapeutics Inc Randomized Withdrawal Period of Study C602 Topline Results Call TranscriptSep 26, 2023- Soleno Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- Soleno Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) TranscriptApr 03, 2023
- Soleno Therapeutics Inc at Destiny-PWS TranscriptOct 20, 2020
Soleno Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Good morning. Thank you all for joining the fifth annual Guggenheim Genomic Medicines and Rare Disease Conference. I'm Robert, one of the analysts representing Guggenheim Therapeutics team. Today, we're fortunate to host Soleno Therapeutics Chief Executive Officer, Dr. Anish Bhatnagar. Anish, thanks for joining us.
Thank you. Thanks for having us.
Let's start with a brief intro to the company. What was yours?
Sure. So Soleno is based in the San Francisco Bay Area. We're one of the smaller rare disease companies. So we're focused on a single asset working on a disease called Prader-Willi syndrome. And Prader-Willi syndrome is rare, not ultra-rare. Prevalence is about 10,000 to 20,000 in the US. We've been in a Phase 3 program for the last two, three years, and happy to tell you more about that.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
